ESMO2024| 百利BL-B01D1治疗食管鳞癌数据

文章预览

BL-B01D1, an EGFR x her3 bispecific antibody-drug conjugate (ADC), in patients with locally advanced or metastatic esophageal squamous cell carcinoma (ESCC) Background BL-B01D1 is a potentially first-in-class ADC comprised of an EGFR x HER3 bispecific antibody attached to a novel topoisomerase I inhibitor payload (Ed-04) via a tetrapeptide-based cleavable linker. We now present safety/efficacy data from a phase I study of BL-B01D1 in ESCC. Methods This phase I study included patients with locally advanced or metastatic gastrointestinal cancers. In the dose-expansion phase, the enrolled ESCC patients were mainly administered at doses of 2.0, 2.5 and 3.0 mg/kg D1D8 Q3W. Results As of Jan 31st, 2024, 83 previously treated ESCC patients were enrolled in Q3W treatment schedule with 22 patients treated at 2.0 mg/kg, 60 patients at 2.5mg/kg and 1 patient at 3.0mg/kg. Among the enrolled ESCC patients, 94.0% (78/83) had received anti-PD-1/L1 and platinum-based chemotherapy in combinatio ………………………………